TipRanks
Go Ultimate55% OFF

AFLAC (AFL) AI Stock Analysis

DE:AFL

AFLAC

(XETRA:AFL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong profitability and conservative balance sheetAflac combines high profitability with conservative capitalization, including zero reported TTM debt, rising equity, and a healthy return on equity. This financial foundation supports resilience through claims volatility, preserves flexibility for investment and capital returns, and strengthens the durability of its insurance franchise.
Negative Factors
Weak and volatile top-line growthThe sharp TTM revenue contraction, following a prior-year decline, raises concern about the durability of premium and investment-related growth despite strong margins. Persistent top-line weakness could constrain operating leverage, reduce reinvestment capacity, and make future earnings more dependent on underwriting or portfolio factors.

AFLAC (AFL) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%25%DE:AFL+21.68%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 62.11B
Dividend Yield
1.85%
Average Volume (3M)
151
Price to Earnings (P/E)
13.3
Beta (1Y)
0.13
Revenue Growth
5.76%
EPS Growth
95.36%
Country
Germany
Employees
12,716
Sector
Financial
Sector Strength
68
Industry
Insurance - Life

AFLAC Business Overview & Revenue Model

Company Description

Aflac Incorporated, operating through its various subsidiary companies, focuses on delivering supplementary health and life insurance policies. The firm's business activities are structured into two primary divisions: Aflac Japan and Aflac U.S. In Ja...

AFLAC Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:2.66%|Next Earnings Date:Feb 03, 2026
Earnings Call SentimentPositive

The call conveyed a generally positive tone: management highlighted solid capital ratios, strong shareholder returns, active investment portfolio repositioning expected to boost recurring income, and product momentum in both Japan (Tsumitasu, Anshin Palette) and U.S. group/dental & vision channels. Offsetting issues were modest — near-term sales comparisons in Japan versus a strong 2025 quarter, a small decline in adjusted book value per share, some investment income shortfalls, elevated lapse/reissue activity on new Japan products and higher U.S. group disability claims. Management maintained constructive outlooks for capital deployment, reserve/reinsurance actions and premium growth (2025–2027 net earned premium CAGR guidance of 3%–6%), suggesting that positives outweigh the contained challenges.

Positive Updates

Adjusted EPS Growth (Excluding FX)
Adjusted earnings per diluted share rose 1.1% year-over-year to $1.80 excluding the effect of foreign currency; GAAP net earnings per diluted share reported at $1.63 (adjusted per Dan: $1.75).

Negative Updates

Japan Q2 Sales Compression vs Strong 2025 Comparisons
Aflac Japan sales declined 5.6% in Q2 (reported as JPY 19.6 billion in transcript) versus a strong Q2 2025 comp (Miraito launch). Net earned premiums in yen declined 3.7% for the quarter and underlying earned premiums (ex-reinsurance/paid-up/DPL effects) fell 1.4%.

Company Guidance

Guidance highlights: management expects Aflac Japan sales to exceed 2025 and now sees Japan’s full‑year benefit ratio at the high end of its 60%–63% guidance (ytd 63.4%; Q2 Japan benefit ratio 64%), with Japan persistency 92.7% (Q2) and U.S. persistency 79.4%; company-level net earned premium growth in 2026 is expected to be just below the prior 3%–6% guidance (U.S. Q2 net earned premium +2.3%; Japan Q2 net earned premiums −3.7% in yen, underlying −1.4%), while the 2025–2027 net earned premium CAGR is still expected to be 3%–6%. Financial targets and capital metrics cited include adjusted EPS up ~1.1% ex‑FX to about $1.80 (reported adjusted ~$1.75; net EPS $1.63), adjusted book value per share −4.1% ex‑FX, adjusted ROE 12.7% (16.6% ex‑FX), pretax margins Japan 34.3% and U.S. 20.9%, expense ratios Japan 20.2% and U.S. 36.1%, U.S. benefit ratio 49.5% (Q2, +220 bps YoY), Aflac Inc. unencumbered liquidity $3.3B ($2.3B above $1B minimum), adjusted leverage 21.8% (target 20%–25%), estimated ESR 226% (240% with USP), combined RBC slightly above 600%, and continued capital returns ($1.3B to shareholders in Q2 — $983M buybacks and $309M dividends; $2.6B YTD); portfolio actions included $4.8B repositioned and an anticipated annualized NII uplift of >$50M.

AFLAC Risk Analysis

AFLAC disclosed 28 risk factors in its most recent earnings report. AFLAC reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

AFLAC Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:AFL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
METMET79Outperform$63.56B19.0512.94%2.32%8.96%-11.62%
UNMUNM76Outperform$14.43B21.246.43%2.12%3.34%-48.74%
PRUPRU70Outperform$40.18B10.4412.00%4.77%9.38%144.26%
GLGL69Neutral$12.23B10.4519.46%0.79%5.62%8.87%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
LNCLNC64Neutral$7.85B3.4221.99%4.39%12.32%97.86%

* Financial Sector Average

Performance Comparison

0%20%40%DE:AFLLNCMETPRUGLUNMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:AFL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:AFLAFLAC Incorporated111.7521.3623.63%
LNCLincoln National41.012.235.74%
METMetlife100.0223.0129.87%
PRUPrudential Financial116.4517.0817.19%
GLGlobe Life Inc.159.0829.5022.76%
UNMUnum Group91.1419.8927.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.